Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 45.4% in September

Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 255,300 shares, a growth of 45.4% from the September 15th total of 175,600 shares. Based on an average daily volume of 4,560,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.3% of the company’s shares are short sold.

Virax Biolabs Group Price Performance

Shares of Virax Biolabs Group stock remained flat at $1.79 on Friday. The company had a trading volume of 105,216 shares, compared to its average volume of 1,231,584. Virax Biolabs Group has a 52 week low of $0.60 and a 52 week high of $9.00. The firm’s 50 day moving average price is $2.80 and its two-hundred day moving average price is $1.65.

Virax Biolabs Group Company Profile

(Get Free Report)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.

Featured Stories

• Five stocks we like better than Virax Biolabs Group
• What is the Euro STOXX 50 Index?
• 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
• How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
• China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
• What Investors Need to Know to Beat the Market
• MarketBeat Week in Review – 10/7 – 10/11